General care for patients with lymphangioleiomyomatosis (LAM) addresses the following findings  :
Pleural effusions - Consider chemical pleurodesis; surgical obliteration of the pleural space; medium-chain triglyceride (MCT [not a component of chyle]), lipid-free diet to reduce chyle flow (utility unknown)
Ascites - Paracentesis, MCT diet (utility unknown)
Airways disease and hypoxemia - Bronchodilators may be of benefit  ; supplemental oxygen, pulmonary rehabilitation, smoking cessation
Standard vaccination for respiratory infections
Osteoporosis - Standard surveillance and treatment; avoid exogenous estrogens 
In May 2015, sirolimus (Rapamune) was the first drug approved by the US FDA for LAM. It has demonstrated improvement in lung function in patients with LAM. Sirolimus also reduces the size of angiomyolipomas, lymphangioleiomyomas, and chylous effusions. The therapeutic response, however, is generally not sustained. [28, 29, 30, 31]
A clinical trial of 89 patients over 12 months showed patients taking Rapamune had a slower decline in lung function than those taking a placebo. After the drug was stopped, the decline in lung function resumed at the same rate as the placebo group. 
Possible options for hormonal manipulation include the following:
Medroxyprogesterone - Utility not known; recent case series does not support its use 
Gonadotropin-releasing hormone agonists - Utility not known; few case reports support their use
Tamoxifen does not appear to be effective  and is not recommended due to estrogen receptor agonist activity
Rate of decline in lung function trends to be less in postmenopausal women (eg, surgical oophorectomy, age)
New experimental therapies include the following:
Chloroquine - Inhibitor of autophagy
Aromatase inhibitors - Antiestrogenic effects
Management of recurrent pneumothoraces or pleural effusions may require surgical intervention; in addition, patients with AML can develop complications (eg, hemorrhage), requiring intervention. Arterial embolization is favored over surgical resection. 
Consider lung transplantation for patients with end-stage pulmonary disease.
The Medscape Transplantation Specialty Center may be helpful.
Pulmonologists help establish the diagnosis and monitor pulmonary function. A pulmonologist can address issues such as vaccinations, oxygen therapy, and pulmonary rehabilitation.
Depending on disease severity, referral to a transplantation center may be beneficial.
Consider patient referral to a center with expertise in lymphangioleiomyomatosis (LAM).
Endocrinologist and/or obstetrician-gynecologist may help address issues involved in hormonal manipulation therapy. An endocrinologist can assist with prophylaxis and treatment of osteoporosis in patients in whom exogenous estrogen is contraindicated.
A urologist may assist with management of renal AML.
A dietitian may help to advise patients on MCT diets for chylous ascites or pleural effusions.
Most patients with lymphangioleiomyomatosis (LAM) do not have special dietary requirements; however, if a patient is on antiestrogen therapies or is postmenopausal and not on estrogen replacement therapy, other cardiac risk factors relevant to diet (eg, cholesterol levels) should be addressed.
Although the use of rapamycin is favored, some patients with chylous effusions or ascites may try an MCT diet (see Medical Care).
Despite the theoretical risk of pneumothorax in patients with lymphangioleiomyomatosis (LAM), studies show no increased risk, even in patients with a prior history.
Some reports suggest worsening of disease during pregnancy. Therefore, specialists generally recommend that caution be exercised when patients consider becoming pregnant. Despite the potential hazards, patients with mild disease have had uneventful pregnancies with little deterioration in lung function.
What would you like to print?